Last updated 2026-06-18
- Raised funding round led by Cactus Capital, Jan 2023
Total raised
—
Last: 2023-01
Stage
Seed
Founded
2023
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
MaxOvary is developing a transducer that enables innovative treatment for Gynecological Diseases using innovative, breakthrough, disposable and non-invasive technology.
The conventional treatment given today to women who have trouble getting pregnant includes physical and mental suffering and provides only a temporary solution.
Funding history · 1 round · — total
2023-01
Undisclosed
Q&A
- What is MaxOvary's primary focus?
- MaxOvary is developing non-invasive solutions for Polycystic Ovary Syndrome (PCOS) and other gynecological diseases using a breakthrough, disposable transducer technology.
- When was MaxOvary founded?
- MaxOvary was founded in January 2023.
- What is the current status of MaxOvary?
- MaxOvary is currently inactive, having ceased operations in December 2024.
- Who is the Co-founder and CEO of MaxOvary?
- Eytan Frey is the Co-founder and CEO of MaxOvary.
- Which investor participated in MaxOvary's funding round in January 2023?
- Cactus Capital participated in MaxOvary's funding round in January 2023.
- What sector does MaxOvary operate in?
- MaxOvary operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
Verified
Tags
non-invasivepregnancyfemtechwomen-healthgynecologymedical-devices
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2023-1 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Dec 2024 ceased to operate |